Parents' experiences with requesting carrier testing for their unaffected children by Vears, Danya et al.
1© American College of Medical Genetics and Genomics Original research article
INTRODUCTION
Some parents are interested in having carrier testing for auto-
somal recessive and X-linked genetic conditions performed 
for their other children following the diagnosis of an affected 
child.1–5 However, the majority of international guidelines 
addressing carrier testing in minors recommend against testing 
when there is no medical benefit.6–10 These guidelines generally 
suggest that testing be postponed until the child can consent to 
testing to protect the psychosocial well-being and future auton-
omy of the child.7,11 Although the recommendations by profes-
sional bodies have remained relatively consistent, they have 
become more nuanced, with some revised guidelines placing 
less importance on preserving the child’s autonomy.9,12
In some cases, carrier testing is carried out for the sibling of 
an affected child despite the recommendations.1,13–19 Studies 
reporting carrier-testing practices of health professionals indi-
cate that genetic health professionals are willing to facilitate 
carrier testing for autosomal recessive and X-linked conditions 
in unaffected children to varying degrees.13–16,20 For example, 
in an interview-based study of 17 key informant genetic health 
professionals in Australia, we found that all our participants 
initially recommended against carrier testing in children fol-
lowing parental requests, with some preemptively discussing it 
as a test they generally do not perform.13 However, although 
some participants said they never facilitate carrier testing in 
children younger than age 16 years, others allow parents who 
persist with their request to have their child tested.13 This is in 
contrast to a recent United Kingdom–based study in which 16 
of the 25 health professionals interviewed (64%) recommended 
that parents have carrier testing performed in older siblings fol-
lowing the diagnosis of a child with sickle cell disease, with only 
6 discouraging testing.20
Although there has been some exploration of parents’ per-
spectives on receiving carrier results as an incidental finding 
from newborn screening,21–23 few studies have explored parents’ 
perspectives on carrier testing for their other children following 
the diagnosis of an affected child.1,17–19 Although existing studies 
provide further evidence that some unaffected siblings receive 
carrier testing, little research has explored parents’ experiences 
with the request-to-test process, the impact of knowing a child’s 
carrier status, and whether parents communicate carrier infor-
mation to their children.
To ensure that guidelines for genetics health practice are 
family-centered and represent the experience and needs of 
parents and families affected by a genetic condition, examin-
ing and documenting parents’ experiences and perspectives 
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Purpose: International guidelines generally recommend delaying 
genetic carrier testing in children until the child reaches the age of 
majority or is mature enough to be involved in the decision. Several 
studies have shown that carrier testing of children does occur in some 
instances, particularly in siblings of a child affected with a genetic 
condition. However, little research has explored parents’ experiences 
with the testing process, the impact of knowing a child’s carrier sta-
tus, and whether parents communicate carrier information to their 
children.
Methods: Semistructured interviews were conducted with 33 
parents of children who had one of three genetic conditions (cystic 
fibrosis, hemophilia, and Duchenne muscular dystrophy). Inductive 
content analysis was used to analyze the data.
Results: Eight distinct pathways to carrier testing were distinguish-
able. While some parents had requested testing, others had been 
offered testing and some had received carrier results incidentally 
following testing to exclude affected status. Some parents were dis-
couraged from testing, which led to frustration. Overall, 67% of the 
parents had received carrier results for at least one child, and parents 
were happy to have results, even if their children were carriers.
Conclusion: Despite recommendations against carrier testing, this 
study provides evidence of varying practices and highlights a need to 
review the guidelines.
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provide important empirical data. This research addresses this 
knowledge gap by reporting the results of interviews with par-
ents of children with a genetic condition who had been inter-
ested in having carrier testing performed in their unaffected 
children. In this article, we present parents’ varied experiences 
with requesting or receiving carrier testing for their children, 
their reflections on the impact of results if testing occurred, 
and whether they had communicated that information to their 
children.
MATERIALS AND METHODS
This study used qualitative methods to explore parents’ experi-
ences relating to carrier testing for their unaffected children. 
Parents were recruited purposively through three genetic ser-
vices in three Australian States. Parents were eligible for inclu-
sion if they had: a child with cystic fibrosis (CF), Duchenne 
muscular dystrophy (DMD) or hemophilia; had unaffected 
children who could be carriers; and had been interested in 
knowing the carrier status of their other children. Participants 
were interviewed by telephone using a semistructured inter-
view guide that asked about their experiences with requesting 
and/or receiving carrier testing for their unaffected children.
Interviews were audiorecorded, transcribed verbatim, and 
analyzed using inductive content analysis in which content 
categories were derived from the data rather than predeter-
mined.24–26 Each transcript was coded into broad content cat-
egories. Sections of the data within the broad categories were 
compared, and more specific subcategories were developed. All 
interviews were coded by DV; LG and CD coded a subset to 
confirm the coding scheme.
Informed consent was obtained from all participants. This 
study was approved by the Human Research Ethics Committees 
at the Royal Children’s Hospital, Victoria (ID 33040A); the 
Hunter New England Local Health District, New South Wales 
(ID 13/08/21/5.12); and the Women’s and Children’s Hospital, 




Thirty-two semistructured interviews were conducted with 33 
parents of children with CF (n = 19), hemophilia (n = 10), or 
DMD (n = 3). One interview was conducted with both parents. 
Participants were aged between 26 and 51 years, and 31 of 33 
(94%) were mothers. The 32 families had a combined total of 
84 children. Thirty-eight of these children were affected by a 
genetic condition (1–3 affected children per family). Of the 
remaining 46 unaffected children, 45 were potential carri-
ers. One child was an unaffected male in a family with DMD. 
Interviews were conducted 2.5–21 years after the diagnosis of 
the first affected child in the core family (mean = 6.5 years).
Pathways of carrier testing in children
Parents reported a range of experiences; eight distinct path-
ways were distinguishable (Figure 1). Pathways diverged at 
three points: the “request phase,” the “testing phase,” and the 
“results phase.” Data analysis showed no discernible differences 
between responses of parents of children with an autosomal 
recessive condition (CF) and an X-linked condition (hemo-
philia and DMD), even though this might have been expected. 
The information shown below each representative quote from 
the responses is formatted as follows:
Participant pseudonym: condition: whether children 
received testing: ages at which children were tested: chil-
dren’s carrier status
Request phase
In 14 of the 32 families, the parents had inquired about or 
requested carrier testing for their other children (pathways 
1 and 2). Most parents reported that they had asked about test-
ing around the time of the diagnosis of their affected child. 
Seven of the 32 families had been offered the option of having 
carrier testing in their other child or children by a genetic coun-
selor or a member of the treating team rather than requesting 
testing (pathways 3 and 4).
The remaining 11 parents (pathways 5–8) had neither been 
offered nor requested carrier testing. Two parents (pathway 5) 
expressed a desire for testing during the interview, but they had 
previously been told by a health professional that carrier testing 
would not be performed until their child was older and had 
simply accepted that at the time. In the children of the other 
nine parents, testing had been performed as part of investiga-
tions to determine whether their child (pathways 6 and 7) or 
fetus (pathway 8) was affected, so carrier results were essentially 
an incidental finding that emerged during the process of testing 
for affected status.
Testing phase
Of the 45 unaffected potential carriers across the 32 families, 30 
had received carrier testing (67%), equating to 22 of 33 (67%) 
parents having received carrier testing in at least one unaffected 
child. Overall, carrier testing took place prenatally in 7 of 30 
(23%) and in childhood in 23 of 30 (77%). Of the 23 children 
tested in childhood, 11 (48%) had blood drawn and 12 (52%) 
had testing performed using the blood from their stored new-
born screening card.
For the 7 parents who requested and received testing (path-
way 2), the mean age at which testing took place in their children 
was 7.5 years (range 0–16 years), with one parent specifically 
requesting to know the carrier result of the fetus after prenatal 
testing. For the six parents who were offered and received test-
ing (pathway 3), the mean age at which testing took place in 
their children was 1.5 years (range 0–7 years), with two parents 
offered carrier results prenatally.
Carrier testing identified 15 carriers and 12 noncarriers 
(see Table 1). For three children from one family, results were 
unknown because testing had been performed on stored blood 
spots to exclude affected status (pathway 6) and the parents 
were informed the child was unaffected, but the carrier results 
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were being held by the genetic service until the children were 
older, which the parents accepted.
Within pathway 2, three parents reported being encouraged 
to postpone testing in their children and having to convince 
health-care staff to allow testing to take place. The experiences 
of these parents varied. One parent expressed gratitude that she 
had not needed to be too persistent.
I think I had spoken to [name of treating doctor] about it 
a couple of times asking him if I could or whether or not 
it was important. And he sort of said, well, at the moment 
I don’t think it’s a necessity…but he was quite obliging I 
s’pose to me at the time after [child with haemophilia] 
had been so sick…which I’m sort of thankful for because I 
don’t think I would have liked to have to argue it.
Alyssa: HA: Tested: 4y and 6y: Noncarriers
The second parent explained her frustration at needing 
to circumvent the nurse on the treating team, seeking the 
authority of the treating clinician for testing after repeated 
refusals.
I kind of went over their head, and at the next appointment 
that we actually saw the doctor I brought it up and he was 
fine with it. He didn’t have an issue but the nurse really did 
have an issue with it, so she was kind of pushing us back to 
wait. I mean when you’re told you have to wait 10 years to 
find out something about your kid that’s already written in 
their blood work!
Violet: HA: Tested: 3y: Carrier
The final parent had been required to present her case in 
front of the hospital ethics committee before testing would be 
facilitated. For these parents, being told they were not allowed 
access to information about their child was not in line with 
their rights as a parent.
I think as a parent you [pause] it’s your child [chuckle]. 
You’re the guardian. You get to decide what that child 
learns or doesn’t learn, or what they can or can’t do. And 
then when someone says no, you can’t do that, that’s not 
your decision, you’re sort of like, you’re taken aback think-
ing, well, this is my child, I have the right to work out 
whether what’s right and what’s wrong.
Felicity: DMD: Tested: 3.5y and 3y: Carriers















































































Table 1 Results for children who underwent carrier testing
Condition Number (%) Carriers Noncarriers Unknowna
Cystic fibrosis 21 (70) 9 9 3
Hemophilia 5 (17) 2 3 0
Duchenne muscular 
dystrophy
4 (13) 4 0 0
Total 30 (100) 15 12 3
aResults were unknown because testing had been performed on stored blood spots 
to exclude affected status and although the parents were informed that the child 
was unaffected, the carrier results were held by the genetic service to be disclosed 
when the children are older.
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Although all three parents eventually received testing, they 
had felt they were fighting to get access to information about 
their children.
Results phase
Some, but not all, parents who requested carrier testing for 
their other children received testing. By contrast, some parents 
who did not specifically request to know the carrier status of 
their children were told the results. Responses of parents within 
these pathways are described.
Parents who requested and received testing (pathways 2 
and 3)
Most parents expressed satisfaction or relief at receiving their 
children’s results. Although a greater number of parents in this 
group found out their children were noncarriers rather than 
carriers, some explained that they were relieved to receive con-
firmation their children were not affected with the genetic con-
dition in the family, regardless of carrier status.
We had him pretty close to [name of child with CF] so I guess 
we were still reeling a bit from that. So it was good news, we 
were quite happy…mainly that he didn’t have CF I guess. I’m 
a carrier and I’m fine. So yeah, it wouldn’t have been a big 
problem if he’d been a carrier really but it’s a bonus that he’s 
not.
Kristy: CF: Tested: Prenatal: Noncarrier
Several parents who had been told their children were carri-
ers said the news had not come as a shock to them and was not 
really a concern.
I think [name of child with hemophilia] was a shock 
because, you know, there was no hemophilia in the fam-
ily. But with [sibling] it was just sort of a bit like saying, oh 
well, she’s got blue eyes or she’s got brown hair...it wasn’t a 
shock or a big deal, or we weren’t upset about it at all. It was 
just, that’s the way she is sort of thing.
Samantha: HA: Tested: 1y: Carrier
Several parents explained that, although they had been upset 
at finding out that their child was a carrier, they were pleased 
that testing had been performed because the certainty gave 
them peace of mind.
Yeah, I think it was a disappointment. But there was a 
50/50 chance…it wasn’t easy to take but…it was final. We 
know what the result is. We know the circumstances. We 
know what the future means.
Felicity: DMD: Tested: 3.5y and 3y: Carriers
When asked, several parents said knowing their child’s car-
rier status had not been of any use to them so far. However, 
some felt it would be helpful later, particularly so that their 
children could be aware of their reproductive risks. One parent 
explained how she found it empowering to have knowledge 
about her child and that it would help her communicate the 
information to her child.
It’s certainly been of no use to him, obviously. He’s only 5. 
But to me, I like having the knowledge in the back of my 
head. I think knowledge is power and you can make your 
decisions later on in life on how you broach the subject 
with him.
Trudy: CF: Tested: Carrier
Parents felt that knowing their child’s carrier status had not 
made them view their child any differently or treat them in a 
negative way.
Parents who requested but did not receive testing 
(pathway 1)
For seven families, testing had not been facilitated following 
their request. Parents reported being told that it was best to wait 
until the child is old enough to make the decision themselves, 
with the health professional often suggesting ages at which 
testing might be appropriate. Some health professionals had 
explained that testing was unnecessary because there were no 
implications for the child at that time. Several parents recalled 
the health professionals mentioning concepts such as consent, 
with one explaining it had been discussed as a requirement for 
testing.
I think we actually asked if we could have her genetically 
tested to see if she was a carrier and we were told no, that 
she would have to give permission herself to have that done 
and she couldn’t do that until she was, I don’t know, 15 or 
16 or something.
Jessica: HA: Not tested
The majority of parents who were denied testing said they 
accepted that testing should be delayed or could understand 
why testing had not been performed. One parent reiterated that 
it was unnecessary, and another mentioned the child’s right to 
privacy. Despite appreciating the reasons for delaying testing, 
some parents still felt it would be good to know their child’s 
carrier status.
Others were not as accepting of the decision not to test their 
children, disagreeing with health professionals’ reasoning. One 
parent who felt that the refusal of the health professionals to 
test was “somewhat ridiculous” explained that she planned to 
re-request next time her child had an appointment.
Parents who received carrier results incidentally (pathways 
7 and 8)
For 8 of 32 parents (25%), genetic testing had been performed 
to exclude affected status in their child either prenatally (n =4) 
or after birth (n =4). These parents had not specifically asked to 
know the carrier status of their fetus or child, and many had not 
expected they would be told this information. Some thought 
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they had not been informed that carrier testing was taking 
place, and others acknowledged they may have been told but 
this had not been their focus at the time.
No, to be honest I didn’t know they were going to tell me 
that. I found it interesting information when they did tell 
me that. But at that point, all I wanted to hear was that no, 
he didn’t have CF. So everything else was a bit of a side 
issue.
Trudy: CF: Tested: Birth: Carrier
Information regarding the child’s carrier status and the pres-
ence or absence of CF was often bundled together by the health 
professionals. Parents who found out incidentally that their 
child did not carry a mutation explained the additional relief 
this provided. By contrast, some parents who were told that 
their child was a carrier experienced mixed emotions.
So she rang me with the results and yeah, I was gobsmacked 
that she wasn’t even a carrier!
Prue: CF: Tested: Prenatal: Noncarrier
I think I was a little bit taken aback because when they said 
no to the CF, I was, like, great! That’s fantastic! But he is a 
carrier. Oh, OK. Well, at least he’s not got CF.
Trudy: CF: Tested: Birth: Carrier
Some parents felt that they would have asked for this infor-
mation regardless, although perhaps later. Others were pleased 
they knew their child’s carrier status but questioned whether 
they would have asked for testing if they had not found out 
incidentally.
We’ve talked about it a lot… Had that initial sweat test not 
[been ambiguous], I think we would have left finding out 
for them. Because being a carrier ultimately is not going 
to affect their life unless they have children with someone 
who is a carrier as well. And then that needs to be their 
decision when they’re old enough to make that decision, 
really.
Rachel: CF: Tested: 3.5y and 3.5y: Noncarriers
DISCUSSION
This is the first study to report the pathways of parents’ experi-
ences with carrier testing in their unaffected children following 
the diagnosis of a child with a genetic condition. We have shown 
that, in line with genetic health professionals’ reports, some chil-
dren in Australia do receive carrier testing.13 This is consistent 
with our previous study of Australian genetic health profession-
als, some of whom reported providing carrier testing.13 Despite 
our purposive sampling for parents who wanted to know their 
child’s carrier status, we found that a similar proportion of par-
ents in our study (67%) had received carrier testing for at least 1 
of their children compared with a cohort of 75 parents of chil-
dren with fragile X syndrome in which 60.7% of their children 
had been tested.19 Although other studies have reported lower 
rates of testing in siblings of children with CF, spinal muscular 
atrophy, and mucopolysaccharidosis, for which 33, 16, and 39% 
of parents, respectively, had received carrier testing for their chil-
dren,1,17,18 they provide further evidence that despite the recom-
mendations a considerable proportion of parents receive carrier 
testing for their children. Studies in other areas of pediatric prac-
tice have highlighted the importance of exploring parents’ expe-
riences relating to the care of their children.27,28 Incorporation 
of their perspectives ensures that practices continue to meet the 
needs of the pediatric patient and their family rather than rely-
ing on the health professionals’ views and assessments.
The interviews elucidated that carrier information may be 
identified incidentally in childhood or prenatally as a by-prod-
uct of genetic testing to exclude affected status in a sibling. Some 
parents were informed about the carrier status of their chil-
dren when they had not specifically asked for this information, 
which seems in direct contrast with genetic health profession-
als’ refusals to provide testing to parents who specifically asked 
to know their child’s carrier status. Although most of the par-
ents in the former group indicated that they were pleased they 
had received this information, some reported that they had not 
realized carrier testing was taking place. Although this does not 
necessarily mean that this was not discussed with the parents 
in genetic counseling sessions, it does indicate that they were 
not given the option to actively choose whether they wanted to 
know this genetic information about their child. This is impor-
tant given that one mother questioned whether she would have 
elected to find out the CF carrier status of her children had she 
been given the choice, and others have reported parents who 
supported delaying carrier testing in order to respect the auton-
omy of their children.2
As one might expect, parents who were told their children 
were not carriers were relieved. However, some parents of chil-
dren with CF who learned that their child was a carrier were 
also relieved, because, for these parents, this information was 
imparted in the context of their child being cleared of actually 
having CF. Likewise, parents in this study were not concerned 
that knowing their child’s carrier status would negatively alter 
the way they viewed or treated their child. Their perception 
corresponds with that of parents in other studies, some of 
whom knew their child’s carrier status.1,19 This is contrary to 
the common assumption in the literature and professional 
guidelines that parents’ perceptions of their children based on 
their carrier status may be harmful for the child.10,16,29–31 These 
findings provide insight into the seemingly benign nature of 
their child’s carrier status, in contrast to the possible outcome 
that their child had a life-threatening condition. These parents’ 
relief may have been enhanced because they had the experi-
ence of parenting an affected child and are well informed about 
the condition. In addition, because all the parents are carri-
ers themselves, they have a good appreciation of the lack of 
health implications associated with their child’s carrier status. 
Therefore, finding out their child’s carrier status for CF was not 
a major concern.
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Although some parents said they accepted health profes-
sionals’ recommendations to postpone carrier testing in their 
children and could understand why testing was “unneces-
sary,” others were less acquiescent. Several parents said that, as 
parents, they have a right to information about their children 
and are therefore entitled to know their carrier status. This has 
also been reported in other studies.2,19 However, in the current 
study, only parents who had initially been told they could not 
have testing made this point. The language these parents used 
suggests that they felt their rights had been challenged, which 
prompted them to adopt a combative stance in order to fight 
to regain the right to make decisions for their children. This 
suggests that outright denial of parents’ requests for carrier test-
ing for their children may have negative consequences, setting 
them on a path of conflict with health professionals. This may 
negatively impact the clinical relationship between the genetic 
health professional and the parents, which may have reper-
cussions for the children’s health if the family then decided to 
break ties with the treating team, or for the children when they 
reached adolescence and wanted more information about their 
risks or reproductive options.
There are several limitations of this study. Because we purpo-
sively recruited parents based on their interest in knowing their 
child’s carrier status, and with a range of testing experiences, the 
proportion of parents in our study who received testing for their 
children may be higher than in the population of affected families 
more broadly. Although this study does not show the frequency 
of carrier testing in the population, it does provide clear evidence 
that, despite the current guidelines, some parents do receive car-
rier testing for their unaffected children in the context of hav-
ing a child with a genetic condition. In addition, our sample 
consists mostly of mothers; however, we did not get a sense that 
the fathers had contradicting views. Also, for a small number of 
participants, the diagnosis of their affected child had taken place 
many years prior, which may alter their recall of the experience.
Conclusions
We identified discrepancies in parents’ access to carrier testing 
in their children, which raises the question of equity. Apparent 
lack of equity in access to a health-care service is, in principle, 
ethically problematic, so further investigation is warranted to 
determine whether ethically unjustified inequity of access is 
occurring.
The findings related to incidental carrier status results also 
raise significant questions. Although this study focused on 
parents who wanted to know their child’s carrier status, it also 
showed we cannot presume that all parents want this informa-
tion. Disclosing carrier information without exploring their 
preferences removes their ability to make decisions about what 
they consider to be in their child’s best interests. Although it is 
not likely to cause significant harm for parents or their children 
if this information is disclosed, we take the view that parents 
should be presented with the option of deciding whether they 
want to know their child’s status when it is identified inciden-
tally. We do not regard it as contentious to argue that parents 
should be given an option not to receive an incidental carrier 
status finding, especially when many in the field believe that 
no carrier-status information should be available to parents. To 
take the argument one step further (a step that is more contro-
versial), it could be argued that if parents are given incidental 
carrier results for their child when they are not actively seek-
ing it, then there is little reason to withhold testing from par-
ents who specifically request carrier testing in their children. 
Although we acknowledge that carrier testing may not always 
be appropriate, for the ethical principle of equity to be given 
due regard, we suggest that all parents be offered the option of 
learning their child’s carrier results unless there are compelling 
ethical reasons specific to an unusual situation in that particu-
lar family. Whether or not carrier testing should take place can 
then be discussed between the parents and the genetic health 
professionals to make the best decision on the basis of individ-
ual circumstances.
ACKNOWLEDGMENTS
D.F.V. acknowledges the support of the Brocher Foundation 
(Geneva, Switzerland), the Research Fund Flanders (Belgium), and 
the Ministère de l’Économie, de l’Innovation et des Exportations 
du Québec, PSR-SIIRI-850 (Canada).
DISCLOSURE
The authors declare no conflict of interest.
REFERENCES
 1. Balfour-Lynn I, Madge S, Dinwiddie R. Testing carrier status in siblings of patients 
with cystic fibrosis. Arch Dis Child 1995;72:167–168.
 2. Barnes C. Testing children for balanced chromosomal translocations: parental 
views and experiences. In: Clarke AJ (ed). The Genetic Testing of Children. BIOS 
Scientific Publishers: Oxford, UK, 1998:51–60.
 3. Fanos JH, Mackintosh MA. Never again joy without sorrow: the effect on 
parents of a child with ataxia-telangiectasia. Am J Med Genet 1999;87: 
413–419.
 4. Brunger JW, Murray GS, O’Riordan M, Matthews AL, Smith RJ, Robin NH. 
Parental attitudes toward genetic testing for pediatric deafness. Am J Hum 
Genet 2000;67:1621–1625.
 5. Kaneko M, Ohashi H, Takamura T, Kawame H. Psychosocial responses to 
being identified as a balanced chromosomal translocation carrier: a qualitative 
investigation of parents in Japan. J Genet Couns 2015;24:922–930.
 6. Human Genetic Society of Australasia. Process of Genetic Counselling. 2008. 
https://www.hgsa.org.au/documents/item/13. Accessed 13 November 2015.
 7. Borry P, Fryns JP, Schotsmans P, Dierickx K. Carrier testing in minors: a systematic 
review of guidelines and position papers. Eur J Hum Genet 2006;14:133–138.
 8. Botkin JR, Belmont JW, Berg JS, et al. Points to consider: ethical, legal, and 
psychosocial implications of genetic testing in children and adolescents. Am J 
Hum Genet 2015;97:6–21.
 9. Lucassen A, Clancy T, Montgomery J, et al. Report on the Genetic Testing of 
Children. British Society for Human Genetics: Birmingham, UK, 2010.
 10. Ross LF, Ross LF, Saal HM, David KL, Anderson RR; American Academy of 
Pediatrics; American College of Medical Genetics and Genomics. Technical 
report: ethical and policy issues in genetic testing and screening of children. 
Genet Med 2013;15:234–245.
 11. Borry P, Evers-Kiebooms G, Cornel MC, Clarke A, Dierickx K; Public and 
Professional Policy Committee (PPPC) of the European Society of Human 
Genetics (ESHG). Genetic testing in asymptomatic minors: background 
considerations towards ESHG recommendations. Eur J Hum Genet 
2009;17:711–719.
 12. British Medical Association Ethics Department. Medical Ethics Today: The BMA’s 
Handbook of Ethics and Law, 3rd edn. Wiley-Blackwell: West Sussex, UK, 2012.
 13. Vears DF, Delany C, Gillam L. Carrier testing in children: exploration of genetic 
health professionals’ practices in Australia. Genet Med 2015;17:380–385.
Genetics in medicine
7Parents’ experiences with requesting carrier testing for unaffected children  |  VEARS et al Original research article
 14. Fryer A. Inappropriate genetic testing of children. Arch Dis Child 2000;83:283–285.
 15. Multhaupt-Buell TJ, Lovell A, Mills L, Stanford KE, Hopkin RJ. Genetic service 
providers’ practices and attitudes regarding adolescent genetic testing for 
carrier status. Genet Med 2007;9:101–107.
 16. Borry P, Goffin T, Nys H, Dierickx K. Attitudes regarding carrier testing in 
incompetent children: a survey of European clinical geneticists. Eur J Hum Genet 
2007;15:1211–1217.
 17. Lavery C. On the receiving end of medicine. In: Clarke AJ (ed) The Genetic 
Testing of Children. BIOS Scientific Publishers: Oxford, UK, 1998.
 18. Meldrum C, Scott C, Swoboda KJ. Spinal muscular atrophy genetic counseling 
access and genetic knowledge: parents’ perspectives. J Child Neurol 
2007;22:1019–1026.
 19. McConkie-Rosell A, Spiridigliozzi GA, Rounds K, et al. Parental attitudes 
regarding carrier testing in children at risk for fragile X syndrome. Am J Med 
Genet 1999;82:206–211.
 20. Noke M, Peters S, Wearden A, Ulph F. A qualitative study to explore how 
professionals in the United Kingdom make decisions to test children for a sickle 
cell carrier status. Eur J Hum Genet 2016;24:164–170.
 21. Lewis S, Curnow L, Ross M, Massie J. Parental attitudes to the identification of 
their infants as carriers of cystic fibrosis by newborn screening. J Paediatr Child 
Health 2006;42:533–537.
 22. Ulph F, Cullinan T, Qureshi N, Kai J. Parents’ responses to receiving sickle cell or 
cystic fibrosis carrier results for their child following newborn screening. Eur J 
Hum Genet 2015;23:459–465.
 23. Kai J, Ulph F, Cullinan T, Qureshi N. Communication of carrier status information 
following universal newborn screening for sickle cell disorders and cystic 
fibrosis: qualitative study of experience and practice. Health Technol Assess 
2009;13:1–82, iii.
 24. Schamber L. Time-line interviews and inductive content analysis: their 
effectiveness for exploring cognitive behaviors. J Am Soc Inf Sci 2000;51: 
734–744.
 25. Downe-Wamboldt B. Content analysis: method, applications, and issues. Health 
Care Women Int 1992;13:313–321.
 26. Graneheim UH, Lundman B. Qualitative content analysis in nursing research: 
concepts, procedures and measures to achieve trustworthiness. Nurse Educ 
Today 2004;24:105–112.
 27. Garwick AW, Kohrman C, Wolman C, Blum RW. Families’ recommendations for 
improving services for children with chronic conditions. Arch Pediatr Adolesc 
Med 1998;152:440–448.
 28. Homer CJ, Marino B, Cleary PD, et al. Quality of care at a children’s hospital: the 
parent’s perspective. Arch Pediatr Adolesc Med 1999;153:1123–1129.
 29. Nelson RM, Botkin JR, Kodish ED, et al. Ethical issues with genetic testing in 
pediatrics. Pediatrics 2001;107:1451–1455.
 30. Clarke A. The genetic testing of children. J Med Genet 1995;32:492.
 31. American Society of Human Genetics Board of Directors, American College 
of Medical Genetics Board of Directors. Points to consider: ethical, legal, and 
psychosocial implications of genetic testing in children and adolescents. Am J 
Hum Genet 1995;57:1233–1241.
Genetics in medicine
